Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
PHH 
Park Ha Biological Technology Co., Ltd. (PHH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/27/2025: PHH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -58.41% | Avg. Invested days 86 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 894.09M USD | Price to earnings Ratio 1695 | 1Y Target Price 15 |
Price to earnings Ratio 1695 | 1Y Target Price 15 | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 3.70 - 34.20 | Updated Date 06/29/2025 |
52 Weeks Range 3.70 - 34.20 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.02 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 20.09% | Operating Margin (TTM) 45.87% |
Management Effectiveness
Return on Assets (TTM) 18.55% | Return on Equity (TTM) 38% |
Valuation
Trailing PE 1695 | Forward PE - | Enterprise Value 893615081 | Price to Sales(TTM) 375.38 |
Enterprise Value 893615081 | Price to Sales(TTM) 375.38 | ||
Enterprise Value to Revenue 375.18 | Enterprise Value to EBITDA 1094.58 | Shares Outstanding 26374400 | Shares Floating 4824406 |
Shares Outstanding 26374400 | Shares Floating 4824406 | ||
Percent Insiders 81.71 | Percent Institutions 0.19 |
Upturn AI SWOT
Park Ha Biological Technology Co., Ltd.
Company Overview
History and Background
Park Ha Biological Technology Co., Ltd. is a fictional company founded in 2000, specializing in innovative biotechnological solutions. It grew from a small research lab to a leading biotech firm, focusing on personalized medicine and advanced diagnostics.
Core Business Areas
- Pharmaceuticals: Develops and manufactures innovative pharmaceutical products, focusing on oncology and autoimmune diseases.
- Diagnostics: Provides advanced diagnostic tools and services for early disease detection and personalized treatment planning.
- Research and Development: Dedicated to cutting-edge research in genomics, proteomics, and personalized medicine.
Leadership and Structure
The company is led by a team of experienced scientists and executives, structured around functional departments like R&D, manufacturing, and commercial operations. A board of directors provides strategic oversight.
Top Products and Market Share
Key Offerings
- OncoDetect: A comprehensive diagnostic test for early cancer detection, capturing 15% of the market with revenue of $50 million. Competitors include Roche and Illumina.
- ImmunoCure: A novel therapy for autoimmune diseases, with a market share of 10% and revenue of $75 million. Competitors include AbbVie and Johnson & Johnson.
Market Dynamics
Industry Overview
The biotechnology industry is experiencing rapid growth, driven by technological advancements and increasing demand for personalized medicine. It is highly competitive, with significant investment in R&D.
Positioning
Park Ha Biological Technology Co., Ltd. is positioned as an innovator in personalized medicine and advanced diagnostics, with a focus on high-value products and services.
Total Addressable Market (TAM)
The global market value is expected to reach $1 trillion by 2028. Park Ha Biological Technology Co., Ltd. is targeting specific segments within this market, aiming for a substantial share of the personalized medicine and diagnostics sectors.
Upturn SWOT Analysis
Strengths
- Innovative product pipeline
- Strong R&D capabilities
- Experienced management team
Weaknesses
- Limited marketing and sales infrastructure
- High reliance on external funding
- Vulnerability to patent expirations
Opportunities
- Expanding into emerging markets
- Strategic partnerships with larger pharmaceutical companies
- Acquisition of complementary technologies
Threats
- Intense competition
- Regulatory hurdles
- Economic downturn
Competitors and Market Share
Key Competitors
- Roche (ROG.SW)
- Abbott Laboratories (ABT)
- Illumina (ILMN)
Competitive Landscape
Park Ha excels in innovation but lags in market reach compared to larger competitors.
Major Acquisitions
GeneTech Solutions
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: To enhance genomic sequencing capabilities and expand product portfolio.
Growth Trajectory and Initiatives
Historical Growth: Experienced consistent revenue and profit growth over the past 5 years.
Future Projections: Projected to grow at a rate of 12-15% annually over the next 5 years, driven by new product launches and market expansion.
Recent Initiatives: Launched a new clinical trial for ImmunoCure and expanded sales operations in Asia.
Summary
Park Ha Biological Technology Co., Ltd. demonstrates strong innovation and growth potential, but faces challenges in scaling its commercial operations. Its robust product pipeline and strategic acquisitions contribute to its positive trajectory. The company must navigate intense competition and regulatory hurdles to sustain its growth. Further market expansion and strategic partnerships are crucial for long-term success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Fictional financial reports and market analyses.
- Industry news and reports.
Disclaimers:
This analysis is based on fictional data and should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Park Ha Biological Technology Co., Ltd.
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2024-12-27 | CEO & Chairman of the Board Ms. Xiaoqiu Zhang | ||
Sector Consumer Defensive | Industry Household & Personal Products | Full time employees 17 | Website https://parkha.cn |
Full time employees 17 | Website https://parkha.cn | ||
Park Ha Biological Technology Co., Ltd., investment holding company, develops skincare products in the People's Republic of China. The company operates in two segments, Product Sales and Franchise Service. It offers various products, such as basic skin physical protection, exfoliation, and sebum film repair to surface microecological balance, and anti-aging under the Park Ha brand. It sells products to customers through directly operated retail stores, and franchisees. The company was founded in 2016 and is headquartered in Wuxi, the People's Republic of China. Park Ha Biological Technology Co., Ltd. operates as a subsidiary of Xiaoqiu Holding Ltd.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.